Geron Corporation Investors Encouraged to Lead Class Action Lawsuit After Significant Losses
On March 27, 2025, Robbins Geller Rudman & Dowd LLP issued a notice to investors of Geron Corporation (NASDAQ: GERN) regarding potential legal actions stemming from significant financial losses. The firm indicates that individuals who bought or acquired Geron securities between February 28, 2024, and February 25, 2025, are eligible to seek the role of lead plaintiff in a class action lawsuit against the company. Named in the suit are Geron Corporation and several of its current and former executives, accused of violating securities laws outlined in the Securities Exchange Act of 1934.
The class action, filed as Dabestani v. Geron Corporation (No. 25-cv-02507), is rooted in allegations that the company misled investors regarding its financial health, particularly in connection with its primary product, the telomerase inhibitor known as Rytelo. Assertions were made that Geron had reliable information about projected revenue and growth, while downplaying risks related to seasonality and external economic factors. Yet, the complaint argues, the optimistic modeling of Rytelo's market performance failed to consider the realities of competitor presence, seasonality's impact, and the burden of ongoing patient treatment monitoring.
A recent announcement on February 26, 2025, further deepened concerns as Geron publicly disclosed that Rytelo's growth had stalled, which was attributed to increased competition, a lack of market awareness, and the necessary regulatory monitoring associated with the drug's usage. This news triggered a notable decline in Geron's stock price, which plummeted by more than 32%, prompting major alarm amongst investors.
As per the Private Securities Litigation Reform Act of 1995, any investor who met the purchase criteria during the Class Period can put forth a request to be appointed as lead plaintiff. The selected lead plaintiff would represent the interests of all affected shareholders in guiding the ongoing legal proceedings against Geron. Importantly, one’s participation as lead plaintiff does not dictate eligibility for any potential recovery from the lawsuit, thus widening options for investors.
Robbins Geller Rudman & Dowd LLP, renowned for championing investor rights, stands as a leading law firm in the field of securities litigation—having reportedly secured over $2.5 billion in recoveries from class action cases in 2024 alone. Their track record further includes history-making settlements, making them a prominent advocate for stakeholders in complex securities fraud cases.
For affected Geron investors wishing to assert their standing in this legal process, they are encouraged to contact the attorneys at Robbins Geller to gather further information regarding their options and rights. As deadlines approach, timely action could prove pivotal for those looking to reclaim their losses due to the alleged misconduct by Geron Corporation.
For additional details on filing a claim or becoming involved in the class action, visit the Robbins Geller website or reach out directly to their legal team via the contact information provided. With the current financial landscape, now is the time for investors to evaluate their standing and take assertive action as necessary.
The class action, filed as Dabestani v. Geron Corporation (No. 25-cv-02507), is rooted in allegations that the company misled investors regarding its financial health, particularly in connection with its primary product, the telomerase inhibitor known as Rytelo. Assertions were made that Geron had reliable information about projected revenue and growth, while downplaying risks related to seasonality and external economic factors. Yet, the complaint argues, the optimistic modeling of Rytelo's market performance failed to consider the realities of competitor presence, seasonality's impact, and the burden of ongoing patient treatment monitoring.
A recent announcement on February 26, 2025, further deepened concerns as Geron publicly disclosed that Rytelo's growth had stalled, which was attributed to increased competition, a lack of market awareness, and the necessary regulatory monitoring associated with the drug's usage. This news triggered a notable decline in Geron's stock price, which plummeted by more than 32%, prompting major alarm amongst investors.
As per the Private Securities Litigation Reform Act of 1995, any investor who met the purchase criteria during the Class Period can put forth a request to be appointed as lead plaintiff. The selected lead plaintiff would represent the interests of all affected shareholders in guiding the ongoing legal proceedings against Geron. Importantly, one’s participation as lead plaintiff does not dictate eligibility for any potential recovery from the lawsuit, thus widening options for investors.
Robbins Geller Rudman & Dowd LLP, renowned for championing investor rights, stands as a leading law firm in the field of securities litigation—having reportedly secured over $2.5 billion in recoveries from class action cases in 2024 alone. Their track record further includes history-making settlements, making them a prominent advocate for stakeholders in complex securities fraud cases.
For affected Geron investors wishing to assert their standing in this legal process, they are encouraged to contact the attorneys at Robbins Geller to gather further information regarding their options and rights. As deadlines approach, timely action could prove pivotal for those looking to reclaim their losses due to the alleged misconduct by Geron Corporation.
For additional details on filing a claim or becoming involved in the class action, visit the Robbins Geller website or reach out directly to their legal team via the contact information provided. With the current financial landscape, now is the time for investors to evaluate their standing and take assertive action as necessary.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.